A comparative study of efficacy and safety of vildagliptin against metformin in newly diagnosed patients of type 2 diabetes mellitus

Pratik Pradip Wadivkar; Vijay Ramakrishna Zad; Kalpana Unind Shah; Nishikant Nandlal Mankar; Monali Pradeep Vakharia

doi:10.18203/2320-6012.ijrms20164539

Authors

Pratik Pradip Wadivkar Department of Pharmacology, Dr. V. M. Government Medical College, Solapur, Maharashtra, India
Vijay Ramakrishna Zad Department of Pharmacology, Dr. V. M. Government Medical College, Solapur, Maharashtra, India
Kalpana Unind Shah Department of Pharmacology, Dr. V. M. Government Medical College, Solapur, Maharashtra, India
Nishikant Nandlal Mankar Department of Pharmacology, Dr. V. M. Government Medical College, Solapur, Maharashtra, India
Monali Pradeep Vakharia Department of Pharmacology, Dr. V. M. Government Medical College, Solapur, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20164539

Keywords:

Metformin, HbA1c, Obesity, T2DM, Vildagliptin

Abstract

Background: Diabetes mellitus is a progressive disease characterised by declining β-cell function. Cornerstone of effective management of T2DM is maintaining strict glycaemic control through agency of various oral hypo-glycaemic agents (OHAs). Metformin (a biguanide) currently forms the preferred treatment in newly diagnosed patients of T2DM. Vildagliptin is a potent, orally administered, competitive and reversible inhibitor of DPP-4, which was launched in 2006 and is now approved in more than 70 countries worldwide.

Methods: The study was a single blinded study conducted in a district level tertiary care hospital attached to a medical teaching institute. Newly diagnosed patients were screened and randomised in two groups. Group 1 received metformin (500 mg) twice daily and group 2 received vildagliptin (50 mg) twice daily. FPG, PPPG, HbA1c and Weight were assessed on week 0 and week 12.

Results: At the end of 12 weeks, ∆FPG was 39.33±4.72mg/dL and 37.84±6.58mg/dL with metformin and vildagliptin respectively. ∆PPPG was 73.88±13.80 mg/dL and 65.08±13.00mg/dL with metformin and vildagliptin. ∆HbA1c was 1.12±0.46 and 0.95±0.32 with metformin and vildagliptin. ∆Weight was 1.02±0.90 Kg with metformin and 0.69±1.33 Kg.

Conclusions: Vildagliptin offers an alternative mode of therapy for newly diagnosed, obese patients of type 2 DM, especially those with impaired fasting plasma glucose.

Metrics

Metrics Loading ...

References

Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg. 2003;58(6):335-41.

U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995.

Joshi SR, Parikh RM. India - Diabetes capital of the world: Now heading towards hypertension. J Assoc Physicians India. 2007;55:323-4.

Kumar A, Goel MK, Jain RB, Khanna P, Chaudhary V. India towards diabetes control: Key issues. Australas Med J. 2013;6(10):524-31.

Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125(3):217-30.

Powers AC, Dalessio D. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia. In: Burton LL, editor. Goodman and Gilman’s Pharrmacological Basis of Therapeutics. 12th edition. New York: McGraw Hill Education; 2011;1237-74.

Kirpichnikov D, McFarlane SI SJ. Metformin: an update. Ann Intern Med. 2002;137:25-33.

Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B (12) deficiency in patients receiving metformin. Arch Intern Med. 2006;166(18):1975-9.

Han J, Kim S, Hong S, Kim S. Metformin-associated Lactic Acidosis: Predisposing Factors and Outcome. Endocrinol Metab. 2014;30:78-83.

Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929-40.

Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705.

Ahrén B, Foley JE. The islet enhancer vildagliptin: Mechanisms of improved glucose metabolism. Int J Clin Pract. 2008;62(SUPPL. 159):8-14.

Masur K, Thâevenod F, Zèanker KS. Diabetes and cancer: epidemiological evidence and molecular links. 1st ed. Masur K, Thévenod F, S ZK, editors. Basel: S. Karger Ag (switzerland); 2008;8:148.

Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of Type 2 diabetes. J Assoc Physicians India. 2011;59(4):237-45.

Dejager S, Razac S, Foley JE SA. Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study. Horm Metab Res. 2007;39(3):218-23.

He YL, Ligueros-Saylan M, Sunkara G, Sabo R, Zhao C, Wang Y, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol. Blackwell Publishing Ltd. 2008;48(1):85-95.

Patel B, Shah J. Safety And Efficacy Of Vildagliptin: Dipeptidyl Peptidase-4 Inhibitor. Int J Pharm Res BIO-SCIENCE. 2012;1(2):35-51.

Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27(12):2874-80.

Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res. Germany. 2009;41(5):368-73.

Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World journal of diabetes. 2010:19-26.

De Luise M. Diabetes mellitus. In: Longo DL, Kasper DL Jameson JL, Fausi AS, Hauser SL LJ, editor. The Medical journal of Australia. 18th ed. New York: McGraw Hill Education; 1993:537-40.

Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose Metabolism and Regulation: Beyond Insulin and Glucagon. Diabetes Spectr. 2004;17(3):183-90.

Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. England. 2007;24(9):955-61.

Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: Comparison with metformin. Horm Metab Res. Germany. 2008;40(12):892-5.

Iwamoto Y, Kashiwagi A, Yamada N, Terao S, Mimori N, Suzuki M, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: A 12-week, randomized, double-blind, active-controlled study. Diabetes, Obes Metab. 2010;12(8):700-8.

Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes, Obes Metab. England. 2009;11(8):804-12.

Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabet Med. England. 2008;25(4):435-41.

Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes, Obes Metab. England. 2009;11(5):506-15.